menu
    • menu
    [{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lotiglipron","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sosei Heptares \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Heptares \/ Pfizer Inc"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Lotiglipron","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sosei Heptares \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Heptares \/ Pfizer Inc"}]

    Find Clinical Drug Pipeline Developments & Deals for Lotiglipron

    Menu

    Lotiglipron

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sosei Heptares

                            Japan arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Sosei Heptares

                            Japan arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lotiglipron

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sosei Heptares Provides Update on Lotiglipron Development

                            Details : PF-07081532 (lotiglipron) is a once-daily, next-generation oral small molecule GLP-1 receptor agonist in development for the treatment of Type 2 diabetes and obesity.

                            Product Name : PF-07081532

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 26, 2023

                            Lead Product(s) : Lotiglipron

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sosei Heptares

                            Japan arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Sosei Heptares

                            Japan arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lotiglipron

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : $1,890.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sosei Heptares' Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Tr...

                            Details : PF-07081532 was discovered by Pfizer scientists during a multi-target research collaboration in which Pfizer had access to Sosei Heptares proprietary StaR® (stabilized receptor) technology. PF-07081532 has successfully completed Phase 1 clinical studies...

                            Product Name : PF-07081532

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 20, 2022

                            Lead Product(s) : Lotiglipron

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : $1,890.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth